159 related articles for article (PubMed ID: 8631036)
21. Immunoconjugates and immunotoxins for therapy of solid tumors.
Hellström I; Trail P; Siegall C; Firestone R; Hellström KE
Cancer Chemother Pharmacol; 1996; 38 Suppl():S35-6. PubMed ID: 8765413
[No Abstract] [Full Text] [Related]
22. [Recombinant immunotoxin for cancer therapy: current status and prospective].
Nagata S
Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658
[No Abstract] [Full Text] [Related]
23. Redesigning nature's poisons to create anti-tumor reagents.
Vitetta ES; Fulton RJ; May RD; Till M; Uhr JW
Science; 1987 Nov; 238(4830):1098-104. PubMed ID: 3317828
[TBL] [Abstract][Full Text] [Related]
24. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
25. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
Robak T
Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
[No Abstract] [Full Text] [Related]
26. Immunotoxins: magic bullets or misguided missiles?
Vitetta ES; Thorpe PE; Uhr JW
Immunol Today; 1993 Jun; 14(6):252-9. PubMed ID: 8397766
[TBL] [Abstract][Full Text] [Related]
27. Immunotoxin therapy of malignancy.
Grossbard ML; Nadler LM
Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
[No Abstract] [Full Text] [Related]
28. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
29. Immunotoxins: magic bullets or misguided missiles?
Vitetta ES; Thorpe PE; Uhr JW
Trends Pharmacol Sci; 1993 May; 14(5):148-54. PubMed ID: 8212309
[TBL] [Abstract][Full Text] [Related]
30. Interferon treatment of human neoplasia.
Strander H
Adv Cancer Res; 1986; 46():1-265. PubMed ID: 2425561
[No Abstract] [Full Text] [Related]
31. The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dong.
Rosenblum M; McLaughlin P
Leuk Lymphoma; 2011 Apr; 52(4):550-1. PubMed ID: 21438824
[No Abstract] [Full Text] [Related]
32. Targeted therapy for hematologic malignancies: has its promise been realized?
Matthews DC; Appelbaum FR; Press OW; Eary JF; Bernstein ID
Curr Opin Hematol; 1995 Jul; 2(4):235-9. PubMed ID: 9372002
[No Abstract] [Full Text] [Related]
33. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
34. Use of antibodies and immunoconjugates for the therapy of more accessible cancers.
Sharkey RM; Goldenberg DM
Adv Drug Deliv Rev; 2008 Sep; 60(12):1407-20. PubMed ID: 18508155
[TBL] [Abstract][Full Text] [Related]
35. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
36. Specific destruction of allogeneic tumor cells in vivo by a bismuth-212 immunotoxin.
Stuart FP; Perdrizet G; Steranka B; Buckingham M; Lopes D; Alvarez V; Rodwell J; McKearn T; Hines J; Atcher R
Transplant Proc; 1987 Feb; 19(1 Pt 1):605-6. PubMed ID: 3274825
[No Abstract] [Full Text] [Related]
37. Monoclonal antibodies in cancer therapy.
Oldham RK
J Clin Oncol; 1983 Sep; 1(9):582-90. PubMed ID: 6366145
[TBL] [Abstract][Full Text] [Related]
38. Immunotoxins for brain tumor therapy.
Oldfield EH; Youle RJ
Curr Top Microbiol Immunol; 1998; 234():97-114. PubMed ID: 9670615
[No Abstract] [Full Text] [Related]
39. Recent developments in immunotoxin therapy.
Ghetie MA; Vitetta ES
Curr Opin Immunol; 1994 Oct; 6(5):707-14. PubMed ID: 7826525
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 receptor-directed therapies: antibody- or cytokine-based targeting molecules.
Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
Adv Nephrol Necker Hosp; 1994; 23():347-56. PubMed ID: 8154364
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
